Physician profile
Luann E Caryl
NPI 1477058105
$3,685.07
in general payments reported to CMS, 2019-2025
17 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $744 · 2024: $1,641 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,041.34 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $633.65 | 2023-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $309.72 | 2024 | Voquezna |
| Lilly USA, LLC | $255.01 | 2023-2025 | Mounjaro, Kisunla |
| Janssen Pharmaceuticals, INC | $233.41 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $206.52 | 2024-2025 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $142.07 | 2025 | Injectafer |
| Abbvie INC. | $124.94 | 2022 | |
| Neurocrine Biosciences, INC. | $119.89 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $116.11 | 2024 | Camzyos |
| Amgen INC. | $115.17 | 2024 | Evenity |
| Axsome Therapeutics, INC. | $114.20 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $97.16 | 2024 | Rexulti |
| Verona Pharma, INC. | $90.00 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $46.48 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $24.00 | 2023 | Wakix |
| Shield Therapeutics INC | $15.40 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Caryl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.